Calyx Announces Closing of Non-Brokered Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN
THE UNITED STATES 


Calyx Bio-Ventures Inc. ("Calyx" or the "Company") (TSX VENTURE:CYX) announces
that, effective today, it closed the non-brokered private placement first
announced on September 4, 2013 and further increased on September 11, 2013 (the
"Private Placement"). The Private Placement consisted of the sale of 3,223,333
units (the "Units") at a price of $0.15 per unit for gross proceeds of $483,500.


Each Unit comprises one common share of the Company and one common share
purchase warrant (each whole warrant, a "Warrant"). Each Warrant is exercisable
into one common share of the Company for a period of 18 months from closing at
an exercise price of $0.35.


In connection with the Private Placement, the Company paid finders fees of
$38,680 and issued 257,866 finders' warrants (the "Finders' Warrants"). Each
Finders' Warrant is exercisable into one common share of the Company for a
period of 18 months from closing at an exercise price of $0.35.


The funds raised will be used for general working capital purposes. The
securities issued will be subject to a standard four month hold period which
will expire January 19, 2014.


The Company is also pleased to announce that Kevin Rathbun has been appointed an
executive officer of the Company. Kevin has been with the Company since early
2012, and his appointment is reflective of his increased involvement in
operations.


About Calyx

Calyx Bio-Ventures Inc. (TSX VENTURE:CYX) is an agricultural technology company
focused on renewable fuels including biojet and biodiesel. Agrisoma Biosciences
Inc., a company in which Calyx is the largest shareholder, is producing a new
proprietary non-food energy feedstock crop, Resonance(R) carinata, which yields
oil that can be refined into fuels that work in existing engines as a 100
percent petroleum substitute. From seed to sky, fuels produced from Resonance(R)
carinata substantially reduce carbon and other harmful emissions, and help to
reduce global petroleum dependence. For further information about Calyx, please
visit www.calyxbio.com. Resonance(R) is a registered trademark of Agrisoma
Biosciences Inc.


Forward-Looking Statements: This document contains certain forward-looking
statements concerning Calyx, as well as other expectations, plans, goals,
objectives, information or statements about future events, conditions, or
performance that may constitute "forward-looking statements" or "forward-looking
information" under applicable securities legislation. Such statements or
information involve substantial known and unknown risks and uncertainties,
certain of which are beyond Calyx's control, including the completion of the
Private Placement and the delay or failure to receive regulatory approvals., 


Such forward-looking statements or information are based on a number of
assumptions, which may prove to be incorrect. In addition to other assumptions
identified in this news release, assumptions have been made regarding, among
other things, timing and completion of the Private Placement, the actual use of
proceeds, and the timing of receipt of regulatory approvals. 


Although Calyx believes that the expectations reflected in such forward-looking
statements or information are reasonable, undue reliance should not be placed on
forward-looking statements because Calyx can give no assurance that such
expectations will prove to be correct. Forward-looking statements or information
are based on current expectations, estimates and projections that involve a
number of risks and uncertainties which could cause actual results to differ
materially from those anticipated by Calyx and described in the forward-looking
statements or information.


The forward-looking statements or information contained in this news release are
made as of the date hereof and Calyx undertakes no obligation to update publicly
or revise any forward-looking statements or information, whether as a result of
new information, future events or otherwise unless so required by applicable
securities laws or the TSX Venture Exchange. The forward-looking statements or
information contained in this news release are expressly qualified by this
cautionary statement.


This press release shall not constitute an offer to sell, nor the solicitation
of an offer to buy, any securities in the United States, nor shall there be any
sale of securities mentioned in this press release in any state in the United
States in which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such state.


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Calyx Bio-Ventures Inc.
Don Konantz
President & CEO
604-649-5961
dkonantz@calyxbio.com


Calyx Bio-Ventures Inc.
Keir Reynolds
Investor Relations
778-998-9242
kreynolds@calyxbio.com
www.calyxbio.com
Calyx Ventures (TSXV:CYX)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024